Teva Pharmaceuticals USA is recalling 133,829 bottles of Mesalamine Delayed-Release Tablets (1.2 gram, 120-count bottles) because the medication failed stability testing. Testing showed the tablets were not dissolving at the required rate, which is critical for how the medication is absorbed by the body. This prescription drug, used to treat certain bowel conditions, was manufactured by Actavis Laboratories and distributed nationwide across the United States and Puerto Rico.
If the tablets do not dissolve as intended, the medication may not be released correctly in the gastrointestinal tract, potentially leading to a lack of efficacy or a reduction in the treatment's intended benefits.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.